BridgeBio Pharma, Inc.
BBIO
$32.19
-$0.82-2.48%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -265.05M | -162.04M | -73.46M | -35.22M | -168.15M |
| Total Depreciation and Amortization | 1.37M | 1.54M | 1.57M | 1.60M | 1.59M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.41M | -17.92M | -99.85M | 39.28M | 19.77M |
| Change in Net Operating Assets | 12.95M | -2.14M | 246.44M | -225.20M | 21.98M |
| Cash from Operations | -195.33M | -180.57M | 74.70M | -219.54M | -124.82M |
| Capital Expenditure | -47.00K | -137.00K | -54.00K | -695.00K | -435.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 0.00 | -42.00K | -98.00K | -- | 0.00 |
| Other Investing Activities | -3.19M | 38.41M | 3.19M | 23.45M | 369.00K |
| Cash from Investing | -3.24M | 38.23M | 3.04M | 22.75M | -66.00K |
| Total Debt Issued | 500.00M | 0.00 | 0.00 | 450.00M | -- |
| Total Debt Repaid | 0.00 | 0.00 | 0.00 | -473.42M | -- |
| Issuance of Common Stock | 2.85M | 2.15M | -- | 318.16M | 333.00K |
| Repurchase of Common Stock | -1.40M | -1.44M | -2.00M | -2.94M | -2.56M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -27.51M | 0.00 | -3.73M | -12.25M | -2.30M |
| Cash from Financing | 473.93M | 707.00K | -5.73M | 279.55M | -4.52M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 275.37M | -141.63M | 72.01M | 82.76M | -129.41M |
